Development of solid lipid nanoparticles-loaded drugs in parasitic diseases
Source abstract
Abstract
Abstract Parasites cause illnesses with broad spectrum of symptoms from mild to severe, and are responsible for a significant number of outbreaks in the world. Current anti-parasitic drugs are toxic and have significant side effects. Nano-carriers are believed to obviate the limitations of conventional drugs via decreasing side effects and increasing target delivery and drug permeability with a controlled prolonged release of a drug. Solid lipid nanoparticles (SLNs) are lipid nanoparticles (LNPs), which have frequently been practiced. Suitable release rate, stability, and target delivery make SLNs a good alternative for colloidal carriers. SLNs are supposed to have great potential to deliver natural products with anti-parasitic properties. Nanoparticles have employed to improve stability and capacity loading of SLNs, during recent years. This review describes development of SLNs, the methods of preparation, characterization, and loaded drugs into SLNs in parasitic diseases. In addition, we summarize recent development in anti-parasitic SLNs-loaded drugs.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Lipid Membrane Structure and Behavior · Advancements in Transdermal Drug Delivery · Insect Pest Control Strategies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Thiruvengadam M, Rajakumar G, Chung IM. Nanotechnology: current uses and future applications in the food industry. 3 Biotechnology. 2018;8(1):74. https://doi.org/10.1007/s13205-018-1104-7.10.1007/s13205-018-1104-7 ↗
2. Nasrollahzadeh M, Sajadi SM, Sajjadi M, Issaabadi Z. Chapter 4-Applications of nanotechnology in daily life. In: Nasrollahzadeh M, Sajadi SM, Sajjadi M, Issaabadi Z, Atarod M, editors. Interf Sci Technol, vol. 28. Amsterdam: Elsevier; 2019. p. 113–43. https://doi.org/10.1016/B978-0-12-813586-0.00004-3.10.1016/B978-0-12-813586-0.00004-3 ↗
3. Neme K, Nafady A, Uddin S, Tola YB. Application of nanotechnology in agriculture, postharvest loss reduction and food processing: food security implication and challenges. Heliyon. 2021;7(12):e08539. https://doi.org/10.1016/j.heliyon.2021.e08539.10.1016/j.heliyon.2021.e08539 ↗
4. Jeevanandam J, Barhoum A, Chan YS, Dufresne A, Danquah MK. Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulations. Beilstein J Nanotechnol. 2018;9:1050–74. https://doi.org/10.3762/bjnano.9.98.10.3762/bjnano.9.98 ↗
5. Zdrojewicz Z, Waracki M, Bugaj B, Pypno D, Cabała K. Medical applications of nanotechnology. Postep Hig Med Doswiad (Online). 2015;69:1196–204. https://doi.org/10.5604/17322693.1177169.10.5604/17322693.1177169 ↗
6. Havel H, Finch G, Strode P, Wolfgang M, Zale S, Bobe I, Youssoufian H, Peterson M, Liu M. Nanomedicines: from bench to bedside and beyond. AAPS J. 2016;18(6):1373–8. https://doi.org/10.1208/s12248-016-9961-7.10.1208/s12248-016-9961-7 ↗
7. Bonifácio BV, Silva PB, Ramos MA, Negri KM, Bauab TM, Chorilli M. Nanotechnology-based drug delivery systems and herbal medicines: a review. Int J Nanomed. 2014;9:1–15. https://doi.org/10.2147/ijn.s52634.10.2147/ijn.s52634 ↗
8. Nemati S, Shalileh F, Mirjalali H, Omidfar K. Toward waterborne protozoa detection using sensing technologies. Front Microbiol. 2023;14:1118164. https://doi.org/10.3389/fmicb.2023.1118164.10.3389/fmicb.2023.1118164 ↗
9. Mirza AZ, Siddiqui FA. Nanomedicine and drug delivery: a mini review. Int Nano Lett. 2014;4(1):1–7.10.1007/s40089-014-0094-7 ↗
10. Watkins R, Wu L, Zhang C, Davis RM, Xu B. Natural product-based nanomedicine: recent advances and issues. Int J Nanomed. 2015;10:6055.
11. Barratt G. Colloidal drug carriers: achievements and perspectives. Cell Mol Life Sci. 2003;60(1):21–37. https://doi.org/10.1007/s000180300002.10.1007/s000180300002 ↗
12. Ventola CL. The nanomedicine revolution: part 1: emerging concepts. Peer Rev J Formular Manag. 2012;37(9):512–25.
13. Havel HA. Where are the nanodrugs? an industry perspective on development of drug products containing nanomaterials. AAPS J. 2016;18(6):1351–3. https://doi.org/10.1208/s12248-016-9970-6.10.1208/s12248-016-9970-6 ↗
14. Caster JM, Patel AN, Zhang T, Wang A. Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017. https://doi.org/10.1002/wnan.1416.10.1002/wnan.1416 ↗
15. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharmaceut Res. 2016;33(10):2373–87. https://doi.org/10.1007/s11095-016-1958-5.10.1007/s11095-016-1958-5 ↗
16. Stanberry LR, Simon JK, Johnson C, Robinson PL, Morry J, Flack MR, Gracon S, Myc A, Hamouda T, Baker JR Jr. Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W805EC combined with approved seasonal influenza antigens. Vaccine. 2012;30(2):307–16. https://doi.org/10.1016/j.vaccine.2011.10.094.10.1016/j.vaccine.2011.10.094 ↗
17. Ventola CL. Progress in nanomedicine: approved and investigational nanodrugs. Peer-Rev J Formul Manag. 2017;42(12):742–55.
18. Gregory AE, Titball R, Williamson D. Vaccine delivery using nanoparticles. Front Cell Infect Microbiol. 2013;3:13. https://doi.org/10.3389/fcimb.2013.00013.10.3389/fcimb.2013.00013 ↗
19. Weers JG. Colloidal particles in drug delivery. Curr Opin Colloid Interf Sci. 1998;3(5):540–4. https://doi.org/10.1016/S1359-0294(98)80030-7.10.1016/S1359-0294(98)80030-7 ↗
20. Nagati V, Tenugu S, Pasupulati AK. Chapter 4-Stability of therapeutic nano-drugs during storage and transportation as well as after ingestion in the human body. In: Das Talukdar A, Dey Sarker S, Patra JK, editors. Advances in nanotechnology-based drug delivery systems. Amsterdam: Elsevier; 2022. p. 83–102. https://doi.org/10.1016/B978-0-323-88450-1.00020-X.10.1016/B978-0-323-88450-1.00020-X ↗
21. Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MdP, Acosta-Torres LS, Diaz-Torres LA, Grillo R, Swamy MK, Sharma S, Habtemariam S, Shin H-S. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol. 2018;16(1):71. https://doi.org/10.1186/s12951-018-0392-8.10.1186/s12951-018-0392-8 ↗
22. Baek J-S, Cho C-W. Surface modification of solid lipid nanoparticles for oral delivery of curcumin: improvement of bioavailability through enhanced cellular uptake, and lymphatic uptake. Eur J Pharmaceut Biopharmaceut. 2017;117:132–40. https://doi.org/10.1016/j.ejpb.2017.04.013.10.1016/j.ejpb.2017.04.013 ↗
23. WHO. Global report on antimalarial efficacy and drug resistance: 2000–2010. WHO; 2010. p. 2023.
24. Murray CJL, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, Fullman N, Naghavi M, Lozano R, Lopez AD. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet. 2012;379(9814):413–31.10.1016/S0140-6736(12)60034-8 ↗
25. Taghipour A, Javanmard E, Rahimi HM, Abdoli A, Matin S, Haghbin M, Olfatifar M, Mirjalali H, Zali MR. Prevalence of intestinal parasitic infections in patients with diabetes: a systematic review and meta-analysis. Int Health. 2023. https://doi.org/10.1093/inthealth/ihad027.10.1093/inthealth/ihad027 ↗
26. Liu LX, Weller PF. Antiparasitic drugs. New Engl J Med. 1996;334(18):1178–84. https://doi.org/10.1056/nejm199605023341808.10.1056/nejm199605023341808 ↗
27. Katz M. Adverse metabolic effects of antiparasitic drugs. Rev Infect Dis. 1982;4(4):768–70. https://doi.org/10.1093/4.4.768.10.1093/4.4.768 ↗
28. Farahmandian I, Arfaa F, Jalali H, Reza M. Comparative studies on the evaluation of the effect of new anthelminthics on various intestinal helminthiasis in Iran. Effects of anthelminthics on intestinal helminthiasis. Chemotherapy. 1977;23(2):98–105. https://doi.org/10.1159/000221977.10.1159/000221977 ↗
29. Khosravi M, Mohammad Rahimi H, Doroud D, Mirsamadi ES, Mirjalali H, Zali MR. In vitro evaluation of mannosylated paromomycin-loaded solid lipid nanoparticles on acute toxoplasmosis. Front Cell Infect Microbiol. 2020;10:33.10.3389/fcimb.2020.00033 ↗
30. Nemati S, Mohammad Rahimi H, Hesari Z, Sharifdini M, Jalilzadeh Aghdam N, Mirjalali H, Zali MR. Formulation of Neem oil-loaded solid lipid nanoparticles and evaluation of its anti-Toxoplasma activity. BMC Complement Med Therap. 2022;22(1):1–11.10.1186/s12906-022-03607-z ↗
31. Pires VC, Magalhães CP, Ferrante M, de Souza RJ, Nguewa P, Severino P, Barral A, Veras PST, Formiga FR. Solid lipid nanoparticles as a novel formulation approach for tanespimycin (17-AAG) against Leishmania infections: preparation, characterization and macrophage uptake. Act Trop. 2020;211:105595.10.1016/j.actatropica.2020.105595 ↗
32. Parvez S, Yadagiri G, Gedda MR, Singh A, Singh OP, Verma A, Sundar S, Mudavath SL. Modified solid lipid nanoparticles encapsulated with amphotericin B and paromomycin: an effective oral combination against experimental murine visceral leishmaniasis. Sci Rep. 2020;10(1):1–14.10.1038/s41598-020-69276-5 ↗
33. Singh A, Yadagiri G, Parvez S, Singh OP, Verma A, Sundar S, Mudavath SL. Formulation, characterization and in vitro anti-leishmanial evaluation of amphotericin B loaded solid lipid nanoparticles coated with vitamin B12-stearic acid conjugate. Mater Sci Eng C. 2020;117: 111279.10.1016/j.msec.2020.111279 ↗
34. Kharaji MH, Doroud D, Taheri T, Rafati S. Drug targeting to macrophages with solid lipid nanoparticles harboring paromomycin: an in vitro evaluation against L. major and L. tropica. AAPS Pharm Sci Tech. 2016;17(5):1110–9.10.1208/s12249-015-0439-1 ↗
35. Heidari-Kharaji M, Taheri T, Doroud D, Habibzadeh S, Badirzadeh A, Rafati S. Enhanced paromomycin efficacy by solid lipid nanoparticle formulation against Leishmania in mice model. Parasit Immunol. 2016;38(10):599–608.10.1111/pim.12340 ↗
36. Jain V, Gupta A, Pawar VK, Asthana S, Jaiswal AK, Dube A, Chourasia MK. Chitosan-assisted immunotherapy for intervention of experimental leishmaniasis via amphotericin B-loaded solid lipid nanoparticles. Appl Biochem Biotechnol. 2014;174(4):1309–30.10.1007/s12010-014-1084-y ↗
37. Omwoyo WN, Melariri P, Gathirwa JW, Oloo F, Mahanga GM, Kalombo L, Ogutu B, Swai H. Development, characterization and antimalarial efficacy of dihydroartemisinin loaded solid lipid nanoparticles. Nanomed Nanotechnol Biol Med. 2016;12(3):801–9.10.1016/j.nano.2015.11.017 ↗
38. Attama AA, Kenechukwu FC, Onuigbo EB, Nnamani PO, Obitte N, Finke JH, Pretor S, Müller-Goymann CC. Solid lipid nanoparticles encapsulating a fluorescent marker (coumarin 6) and antimalarials–artemether and lumefantrine: evaluation of cellular uptake and antimalarial activity. Eur J Nanomed. 2016;8(3):129–38.10.1515/ejnm-2016-0009 ↗
39. Dwivedi P, Khatik R, Khandelwal K, Shukla R, Paliwal SK, Dwivedi AK, Mishra PR. Preparation and characterization of solid lipid nanoparticles of antimalarial drug arteether for oral administration. J Biomater Tissue Eng. 2014;4(2):133–7.10.1166/jbt.2014.1148 ↗
40. Kamarullah W, Indrajaya E, Emmanuella J. potency of luteolin with solid lipid nanoparticle (sln)-polyethylene glycol (peg) modification for artemisinin-resistant Plasmodium falciparum infection. Indonesian J Trop Infect Dis. 2018;7(3):80–6.10.20473/ijtid.v7i3.6726 ↗
41. Volpedo G, Costa L, Ryan N, Halsey G, Satoskar A, Oghumu S. Nanoparticulate drug delivery systems for the treatment of neglected tropical protozoan diseases. J Venom Animal Toxin Includ Trop Dis. 2019;25:e144118. https://doi.org/10.1590/1678-9199-jvatitd-1441-18.10.1590/1678-9199-jvatitd-1441-18 ↗
42. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art. Eur J Pharmaceut Biopharmaceut. 2000;50(1):161–77. https://doi.org/10.1016/s0939-6411(00)00087-4.10.1016/s0939-6411(00)00087-4 ↗
43. Lu H, Zhang S, Wang J, Chen Q. A review on polymer and lipid-based nanocarriers and its application to nano-pharmaceutical and food-based systems. Front Nutr. 2021;8:783831. https://doi.org/10.3389/fnut.2021.783831.10.3389/fnut.2021.783831 ↗
44. Nicolas J, Mura S, Brambilla D, Mackiewicz N, Couvreur P. Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery. Chem Soc Rev. 2013;42(3):1147–235. https://doi.org/10.1039/c2cs35265f.10.1039/c2cs35265f ↗
45. Guimarães D, Cavaco-Paulo A, Nogueira E. Design of liposomes as drug delivery system for therapeutic applications. Int J Pharmaceut. 2021;601:120571. https://doi.org/10.1016/j.ijpharm.2021.120571.10.1016/j.ijpharm.2021.120571 ↗
46. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36–48. https://doi.org/10.1016/j.addr.2012.09.037.10.1016/j.addr.2012.09.037 ↗
47. Jacob S, Nair AB, Shah J, Gupta S, Boddu SHS, Sreeharsha N, Joseph A, Shinu P, Morsy MA. Lipid nanoparticles as a promising drug delivery carrier for topical ocular therapy-an overview on recent advances. Pharmaceutics. 2022. https://doi.org/10.3390/pharmaceutics14030533.10.3390/pharmaceutics14030533 ↗
48. Dhiman N, Awasthi R, Sharma B, Kharkwal H, Kulkarni GT. Lipid nanoparticles as carriers for bioactive delivery. Front Chem. 2021;9:580118. https://doi.org/10.3389/fchem.2021.580118.10.3389/fchem.2021.580118 ↗
49. Uner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomed. 2007;2(3):289–300.
50. Satapathy S, Patro CS. Solid lipid nanoparticles for efficient oral delivery of tyrosine kinase inhibitors: a nano targeted cancer drug delivery. Adv Pharmaceut Bull. 2022;12(2):298–308. https://doi.org/10.34172/apb.2022.041.10.34172/apb.2022.041 ↗
51. Mishra V, Bansal KK, Verma A, Yadav N, Thakur S, Sudhakar K, Rosenholm JM. Solid lipid nanoparticles: emerging colloidal nano drug delivery systems. Pharmaceutics. 2018. https://doi.org/10.3390/pharmaceutics10040191.10.3390/pharmaceutics10040191 ↗
52. Pink DL, Loruthai O, Ziolek RM, Wasutrasawat P, Terry AE, Lawrence MJ, Lorenz CD. On the structure of solid lipid nanoparticles. Small. 2019;15(45):e1903156. https://doi.org/10.1002/smll.201903156.10.1002/smll.201903156 ↗
53. Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages. Res Pharmaceut Sci. 2018;13(4):288–303. https://doi.org/10.4103/1735-5362.235156.10.4103/1735-5362.235156 ↗
54. Sharma S, Parveen R, Chatterji BP. Toxicology of nanoparticles in drug delivery. Curr Pathobiol Rep. 2021;9(4):133–44. https://doi.org/10.1007/s40139-021-00227-z.10.1007/s40139-021-00227-z ↗
55. Khan I, Saeed K, Khan I. Nanoparticles: properties, applications and toxicities. Arab J Chem. 2019;12(7):908–31. https://doi.org/10.1016/j.arabjc.2017.05.011.10.1016/j.arabjc.2017.05.011 ↗
56. Inglut CT, Sorrin AJ, Kuruppu T, Vig S, Cicalo J, Ahmad H, Huang HC. Immunological and toxicological considerations for the design of liposomes. Nanomaterials (Basel, Switzerland). 2020. https://doi.org/10.3390/nano10020190.10.3390/nano10020190 ↗
57. Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev. 2007;59(6):491–504. https://doi.org/10.1016/j.addr.2007.04.008.10.1016/j.addr.2007.04.008 ↗
58. Din FU, Aman W, Ullah I, Qureshi OS, Mustapha O, Shafique S, Zeb A. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int J Nanomed. 2017;12:7291–309. https://doi.org/10.2147/ijn.s146315.10.2147/ijn.s146315 ↗
59. Lingayat VJ, Zarekar NS, Shendge RS. Solid lipid nanoparticles: a review. Nanosci Nanotech Res. 2017;4(2):67–72.
60. Satapathy MK, Yen TL, Jan JS, Tang RD, Wang JY, Taliyan R, Yang CH. Solid lipid nanoparticles (slns): an advanced drug delivery system targeting brain through bbb. Pharmaceutics. 2021. https://doi.org/10.3390/pharmaceutics13081183.10.3390/pharmaceutics13081183 ↗
61. Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Rel. 2005;107(2):215–28. https://doi.org/10.1016/j.jconrel.2005.06.006.10.1016/j.jconrel.2005.06.006 ↗
62. Martins SM, Sarmento B, Nunes C, Lúcio M, Reis S, Ferreira DC. Brain targeting effect of camptothecin-loaded solid lipid nanoparticles in rat after intravenous administration. Eur J Pharmaceut Biopharmaceut. 2013;85(3):488–502. https://doi.org/10.1016/j.ejpb.2013.08.011.10.1016/j.ejpb.2013.08.011 ↗
63. Wang X, Chen H, Luo Z, Fu X. Preparation of starch nanoparticles in water in oil microemulsion system and their drug delivery properties. Carbohydr Polym. 2016;138:192–200. https://doi.org/10.1016/j.carbpol.2015.11.006.10.1016/j.carbpol.2015.11.006 ↗
64. Zur Mühlen A, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery–drug release and release mechanism. Eur J Pharmaceut Biopharmaceut. 1998;45(2):149–55. https://doi.org/10.1016/s0939-6411(97)00150-1.10.1016/s0939-6411(97)00150-1 ↗
65. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47(2–3):165–96. https://doi.org/10.1016/s0169-409x(01)00105-3.10.1016/s0169-409x(01)00105-3 ↗
66. Dikmen G, Guney G, Genc L. Characterization of solid lipid nanoparticles containing caffeic acid and determination of its effects on MCF-7 cells. Recent Patents Anti-Cancer Drug Discov. 2015;10(2):224–32. https://doi.org/10.2174/1574892810666150115124413.10.2174/1574892810666150115124413 ↗
67. Guillot A, Couffin AC, Sejean X, Navarro F, Limberger M, Lehr CM. Solid phase extraction as an innovative separation method for measuring free and entrapped drug in lipid nanoparticles. Pharmaceut Res. 2015;32(12):3999–4009. https://doi.org/10.1007/s11095-015-1761-8.10.1007/s11095-015-1761-8 ↗
68. Venishetty VK, Parikh N, Sistla R, Ahmed FJ, Diwan PV. Application of validated RP-HPLC method for simultaneous determination of docetaxel and ketoconazole in solid lipid nanoparticles. J Chromatogr Sci. 2011;49(2):136–41. https://doi.org/10.1093/chrsci/49.2.136.10.1093/chrsci/49.2.136 ↗
69. Lv Y, He H, Qi J, Lu Y, Zhao W, Dong X, Wu W. Visual validation of the measurement of entrapment efficiency of drug nanocarriers. Int J Pharmaceut. 2018;547(1):395–403. https://doi.org/10.1016/j.ijpharm.2018.06.025.10.1016/j.ijpharm.2018.06.025 ↗
70. Berry MR, Likar MD. Statistical assessment of dissolution and drug release profile similarity using a model-dependent approach. J Pharmaceut Biomed Anal. 2007;45(2):194–200. https://doi.org/10.1016/j.jpba.2007.05.021.10.1016/j.jpba.2007.05.021 ↗
71. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Layloff T, Viswanathan CT, Cook CE, McDowall RD. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet. 1991;16(4):249–55. https://doi.org/10.1007/bf03189968.10.1007/bf03189968 ↗
72. Arvaniti EC, Juenger MCG, Bernal SA, Duchesne J, Courard L, Leroy S, Provis JL, Klemm A, De Belie N. Determination of particle size, surface area, and shape of supplementary cementitious materials by different techniques. Mater Struct. 2015;48(11):3687–701. https://doi.org/10.1617/s11527-014-0431-3.10.1617/s11527-014-0431-3 ↗
73. Kakkar D, Dumoga S, Kumar R, Chuttani K, Mishra AK. PEGylated solid lipid nanoparticles: design, methotrexate loading and biological evaluation in animal models. Med Chem Commun. 2015;6(8):1452–63. https://doi.org/10.1039/C5MD00104H.10.1039/C5MD00104H ↗
74. Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A, Khorasani S, Mozafari MR. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 2018. https://doi.org/10.3390/pharmaceutics10020057.10.3390/pharmaceutics10020057 ↗
75. Xu R. Progress in nanoparticles characterization: sizing and zeta potential measurement. Particuology. 2008;6(2):112–5. https://doi.org/10.1016/j.partic.2007.12.002.10.1016/j.partic.2007.12.002 ↗
76. Pang LSK, Saxby JD, Chatfield SP. Thermogravimetric analysis of carbon nanotubes and nanoparticles. J Phys Chem. 1993;97(27):6941–2. https://doi.org/10.1021/j100129a001.10.1021/j100129a001 ↗
77. Melo MN, Pereira FM, Rocha MA, Ribeiro JG, Junges A, Monteiro WF, Diz FM, Ligabue RA, Morrone FB, Severino P, Fricks AT. Chitosan and chitosan/PEG nanoparticles loaded with indole-3-carbinol: characterization, computational study and potential effect on human bladder cancer cells. Mater Sci Eng C. 2021;124:112089. https://doi.org/10.1016/j.msec.2021.112089.10.1016/j.msec.2021.112089 ↗
78. Esposito E, Sguizzato M, Drechsler M, Mariani P, Carducci F, Nastruzzi C, Cortesi R. Progesterone lipid nanoparticles: Scaling up and in vivo human study. Eur J Pharmaceut Biopharmaceut. 2017;119:437–46. https://doi.org/10.1016/j.ejpb.2017.07.015.10.1016/j.ejpb.2017.07.015 ↗
79. Ravani L, Esposito E, Bories C, Moal VL, Loiseau PM, Djabourov M, Cortesi R, Bouchemal K. Clotrimazole-loaded nanostructured lipid carrier hydrogels: thermal analysis and in vitro studies. Int J Pharmaceut. 2013;454(2):695–702. https://doi.org/10.1016/j.ijpharm.2013.06.015.10.1016/j.ijpharm.2013.06.015 ↗
80. Patil H, Kulkarni V, Majumdar S, Repka MA. Continuous manufacturing of solid lipid nanoparticles by hot melt extrusion. Int J Pharmaceut. 2014;471(1):153–6. https://doi.org/10.1016/j.ijpharm.2014.05.024.10.1016/j.ijpharm.2014.05.024 ↗
81. Carbone C, Tomasello B, Ruozi B, Renis M, Puglisi G. Preparation and optimization of PIT solid lipid nanoparticles via statistical factorial design. Eur J Med Chem. 2012;49:110–7. https://doi.org/10.1016/j.ejmech.2012.01.001.10.1016/j.ejmech.2012.01.001 ↗
82. Nabi-Meibodi M, Vatanara A, Najafabadi AR, Rouini MR, Ramezani V, Gilani K, Etemadzadeh SMH, Azadmanesh K. The effective encapsulation of a hydrophobic lipid-insoluble drug in solid lipid nanoparticles using a modified double emulsion solvent evaporation method. Colloid Surface B Biointerfaces. 2013;112:408–14. https://doi.org/10.1016/j.colsurfb.2013.06.013.10.1016/j.colsurfb.2013.06.013 ↗
83. Kotmakçı M, Akbaba H, Erel G, Ertan G, Kantarcı G. Improved method for solid lipid nanoparticle preparation based on hot microemulsions: preparation, characterization, cytotoxicity, and hemocompatibility evaluation. AAPS Pharm Sci Tech. 2017;18(4):1355–65. https://doi.org/10.1208/s12249-016-0606-z.10.1208/s12249-016-0606-z ↗
84. Battaglia L, Gallarate M, Cavalli R, Trotta M. Solid lipid nanoparticles produced through a coacervation method. J Microencapsul. 2010;27(1):78–85. https://doi.org/10.3109/02652040903031279.10.3109/02652040903031279 ↗
85. Charcosset C, El-Harati A, Fessi H. Preparation of solid lipid nanoparticles using a membrane contactor. J Control Releas. 2005;108(1):112–20. https://doi.org/10.1016/j.jconrel.2005.07.023.10.1016/j.jconrel.2005.07.023 ↗
86. Passerini N, Gavini E, Albertini B, Rassu G, Di Sabatino M, Sanna V, Giunchedi P, Rodriguez L. Evaluation of solid lipid microparticles produced by spray congealing for topical application of econazole nitrate. J Pharm Pharmacol. 2009;61(5):559–67. https://doi.org/10.1211/jpp.61.05.0003.10.1211/jpp.61.05.0003 ↗
87. Souto EB, Doktorovova S, Zielinska A, Silva AM. Key production parameters for the development of solid lipid nanoparticles by high shear homogenization. Pharmaceut Develop Technol. 2019;24(9):1181–5. https://doi.org/10.1080/10837450.2019.1647235.10.1080/10837450.2019.1647235 ↗
88. Nair AB, Shah J, Al-Dhubiab BE, Jacob S, Patel SS, Venugopala KN, Morsy MA, Gupta S, Attimarad M, Sreeharsha N, Shinu P. Clarithromycin solid lipid nanoparticles for topical ocular therapy: optimization, evaluation and in vivo studies. Pharmaceutics. 2021. https://doi.org/10.3390/pharmaceutics13040523.10.3390/pharmaceutics13040523 ↗
89. Pooja D, Tunki L, Kulhari H, Reddy BB, Sistla R. Optimization of solid lipid nanoparticles prepared by a single emulsification-solvent evaporation method. Data Brief. 2016;6:15–9. https://doi.org/10.1016/j.dib.2015.11.038.10.1016/j.dib.2015.11.038 ↗
90. Maleki G, Bahrami Z, Woltering EJ, Khorasani S, Mozafari MR. A review of patents on “Mozafari Method” as a green technology for manufacturing bioactive carriers. Biointerface Res Appl Chem. 2023;13:1.
91. Nasrollahzadeh M, Sajjadi M, Sajadi SM, Issaabadi Z. Chapter 5-Green nanotechnology. In: Nasrollahzadeh M, Sajadi SM, Sajjadi M, Issaabadi Z, Atarod M, editors. An introduction to green nanotechnology, vol. 28. Elsevier; 2019. p. 145–98.10.1016/B978-0-12-813586-0.00005-5 ↗
92. Kumar A. Improving secondary metabolite production in tissue cultures. Plant Biol Biotechnol. 2015;8:397–406.10.1007/978-81-322-2283-5_20 ↗
93. Mozafari MR, Javanmard R, Raji M. Tocosome: novel drug delivery system containing phospholipids and tocopheryl phosphates. Int J Pharmaceut. 2017;528(1–2):381–2. https://doi.org/10.1016/j.ijpharm.2017.06.037.10.1016/j.ijpharm.2017.06.037 ↗
94. Mozafari MR. Nanoliposomes: preparation and analysis. Method Mol Biol (Clifton, NJ). 2010;605:29–50. https://doi.org/10.1007/978-1-60327-360-2_2.10.1007/978-1-60327-360-2_2 ↗
95. Mohammadi L, Pal K, Bilal M, Rahdar A, Fytianos G, Kyzas GZ. Green nanoparticles to treat patients with Malaria disease: an overview. J Molr Struct. 2021;1229:129857.10.1016/j.molstruc.2020.129857 ↗
96. Rahman K, Khan SU, Fahad S, Chang MX, Abbas A, Khan WU, Rahman L, Haq ZU, Nabi G, Khan D. Nano-biotechnology: a new approach to treat and prevent malaria. Int J Nanomed. 2019;14:1401–10. https://doi.org/10.2147/ijn.s190692.10.2147/ijn.s190692 ↗
97. Radwan A, El-Lakkany N, William S, El-Feky G, Al-Shorbagy M, Saleh S, Botros S. A novel praziquantel solid lipid nanoparticle formulation shows enhanced bioavailability and antischistosomal efficacy against murine S. mansoni infection. Parasite Vectors. 2019. https://doi.org/10.1186/s13071-019-3563-z.10.1186/s13071-019-3563-z ↗
98. de Souza AL, Andreani T, de Oliveira RN, Kiill CP, dos Santos FK, Allegretti SM, Chaud MV, Souto EB, Silva AM, Gremião MP. In vitro evaluation of permeation, toxicity and effect of praziquantel-loaded solid lipid nanoparticles against Schistosoma mansoni as a strategy to improve efficacy of the schistosomiasis treatment. Int J Pharm. 2014;463(1):31–7. https://doi.org/10.1016/j.ijpharm.2013.12.022.10.1016/j.ijpharm.2013.12.022 ↗
99. Rafiei A, Soltani S, Ramezani Z, Abbaspour MR, Jelowdar A, Kahvaz MS. Ultrastructural changes on fertile and infertile hydatid cysts induced by conventional and solid lipid nanoparticles of albendazole and albendazole sulfoxide. Compr Clin Pathol. 2019;28(4):1045–53.10.1007/s00580-019-02925-y ↗
100. Soltani S, Rafiei A, Ramezani Z, Abbaspour MR, Jelowdar A, Kahvaz MS. Evaluation of the hydatid cyst membrane permeability of albendazole and albendazole sulfoxide-loaded solid lipid nanoparticles. Jundishapur J Natural Pharmaceut Product. 2017;12:2.